0001157523-18-001710.txt : 20180803 0001157523-18-001710.hdr.sgml : 20180803 20180803163021 ACCESSION NUMBER: 0001157523-18-001710 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180803 DATE AS OF CHANGE: 20180803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Calyxt, Inc. CENTRAL INDEX KEY: 0001705843 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 271967997 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38161 FILM NUMBER: 18992185 BUSINESS ADDRESS: STREET 1: 2800 MOUNT RIDGE ROAD CITY: ROSEVILLE STATE: MN ZIP: 55113 BUSINESS PHONE: (651) 683-2807 MAIL ADDRESS: STREET 1: 2800 MOUNT RIDGE ROAD CITY: ROSEVILLE STATE: MN ZIP: 55113 8-K/A 1 a51848304.htm CALYXT, INC. 8-K/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K/A
(Amendment No. 1)


CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report: (Date of earliest event reported): August 1, 2018


Calyxt, Inc.
(Exact name of registrant as specified in its charter)



Delaware

001-38161

27-1967997

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2800 Mount Ridge Road 
Roseville, MN 55113-1127
(Address and zip code of principal executive offices)

(651) 683-2807
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Explanatory Note

This Amendment No. 1 on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K furnished by Calyxt, Inc. (the “Company”) to the Securities and Exchange Commission (the “SEC”) on August 2, 2018 (the “Form 8-K”). Due to clerical errors, the Form 8-K inadvertently included (i) an outdated address for the Company’s principal executive offices and (ii) an incorrect conformed signature. The original signature for the Form 8-K was obtained from Federico Tripodi, the Company’s Chief Executive Officer, prior to the submission of the Form 8-K. This Amendment is furnished solely to correct such clerical errors by providing the correct address for the Company’s new principal executive offices and correcting the signature page. Other than as specifically set forth in this Amendment with respect to the cover page and signature page, no other modifications to the Form 8-K are being made by this Amendment. The text of Item 2.02 and the press release attached as an exhibit are unchanged from the Form 8-K.

Item 2.02. Results of Operations and Financial Condition.

On August 1, 2018, Calyxt, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2018. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. 

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

d. Exhibits

Exhibit

Number

  Description
99.1 Press Release of Calyxt, Inc. dated August 1, 2018


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Calyxt, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 3, 2018

 

CALYXT, INC

 

By:

/s/ Federico Tripodi

Name:

Federico Tripodi

Title:

Chief Executive Officer


EXHIBIT INDEX

EX-99.1 2 a51848304ex99_1.htm EXHIBIT 99.1

Exhibit 99.1

Calyxt Reports Financial Results for Second Quarter and Half-Year 2018

As of June 30th, successfully contracted over 17,000 high-oleic / no trans-fat soybean acres with 78 growers.

~20 small to large food company customers engaged across food services and food ingredient applications

Calyxt’s high-fiber wheat & improved quality alfalfa transitioned to phase II

Advanced two product candidates from ‘discovery’ to ‘phase 1’ development

Completed move to new concept-to-fork facility in Roseville, Minn.

Successful follow-on offering increases cash position to over $105M

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--August 1, 2018--Calyxt, Inc. (NASDAQ:CLXT), a consumer-centric, food- and agriculture-focused company, today announced its results for the three-month period and the first half period ended June 30, 2018.

The first half of 2018 saw significant growth of the Company’s lead product candidate, a non-GMO, high-oleic soybean variety, designed to yield soybean oil with over 80% oleic oil content that is completely trans fat free. With over 17,000 acres planted, Calyxt surpassed its initial goal of 12,000 acres, with over 90% of existing farmers re-planting. With the commercial launch of this product in the US later this year, Calyxt is well positioned within the industry, following the FDA ban on all trans fats in the U.S. going into effect in 2018. Calyxt also welcomes the recently unveiled World Health Organization’s plan to remove all trans fats worldwide from the food chain by 2023.

The recent move into its new state-of-the-art, farm-to-kitchen facility enables Calyxt to accelerate and expand its product pipeline, with a continued focus on a variety of pressing health- and agronomic needs.


High-Oleic Soybean Update:

  • We successfully completed planting over 17,000 acres with 78 growers. In spite of a wet spring this year, some farmers were still able to plant early. Certain growing regions in our grower network have seen more than average rainfall this year.
  • Over 90% of existing farmers signed up to re-plant Calyxt high-oleic soybeans this year. Furthermore, on average, repeat farmers doubled their Calyxt acres year over year.
  • Our field agronomists are providing in-season technical support to farmers growing Calyxt high-oleic soybean variety so that growers have a positive experience and optimize their farming operations for Calyxt variety.
  • Overall crop quality looks good to excellent.
  • ~20 small to large food company customers engaged across food services and food ingredient applications which includes frying (such as chips and French fries), frying meats, both salty and healthy snacks, baking, nut butter and meat replacement products.

Pipeline Update:

  • Calyxt’s high-fiber wheat and improved quality alfalfa product candidates have advanced to phase II, moving into field-testing.
  • Calyxt has used its proprietary gene editing technology, TALEN®, to produce a small, precise deletion in the wheat genome, an outcome similar to what occurs in nature, to develop its high-fiber wheat product. Calyxt’s high-fiber white flour contains more than three times the amount of dietary fiber than in commodity white flour. A single serving of Calyxt’s high-fiber wheat flour could provide more than 100 percent of the recommended daily value.
  • Calyxt’s improved quality alfalfa targets a reduction in the lignin content of the plant, thus potentially improving its digestibility for animal nutrition. This allows for improved fiber digestibility for the animal, resulting in better animal health, increased milk production and weight gain for beef cattle, as well as more sustainable animal farming
  • Calyxt announced the successful transfer of improved quality alfalfa seed and plants developed by Calyxt at its research and development facility to S&W Seeds for field evaluation and testing. The collaboration between Calyxt and S&W is focused on providing enhanced traits in alfalfa that can drive improved productivity, while decreasing input costs to meet the growing global demand for improved quality alfalfa seeds.

Regulatory & IP:

  • Bayer CropScience agreed to settle a lawsuit brought by Calyxt in the Delaware Chancery Court. Bayer will destroy any technology, related product and confidential information covered by a 2013 License Agreement, and will permanently abandon patent applications that are based on or include data related to the covered technology. This settlement confirms Bayer and its subsidiaries have no access to Calyxt technology or intellectual property.
  • Calyxt’s high-fiber wheat and improved quality alfalfa products have been declared non-regulated articles in March 2018 and October 2017, respectively, under the Biotechnology Regulatory Services’ “Am I Regulated?” process of the Animal and Plant Health Inspection Service (APHIS), an agency of the U.S. Department of Agriculture (USDA). These products are two of a total of seven Calyxt products that have been deemed non-regulated by the USDA, including powdery mildew-resistant wheat, high-oleic soybeans, high-oleic / low-linolenic soybeans, cold storable potatoes and reduced browning potatoes.

Completion of New Facility:

  • We completed our move to our new facility in June and decommissioning of our old facility was completed.
  • Our new facility will provide a framework for automation and super-charging our capabilities to make products in the near future, as well as food company ingredient support capabilities as we launch our high-oleic soybean oil.

Follow-On Offering:

  • On May 22, 2018, Calyxt completed an upsized follow-on offering of its common stock for $60.9M in gross proceeds.
  • Calyxt sold 4,057,500 shares of common stock at $15.00 per share, including 457,500 shares pursuant to the exercise in full, of the underwriters’ option to purchase additional shares and 550,000 shares purchased by Cellectis at $15.00 per share.
  • With a cash balance of $105.6 million at June 30, 2018, we anticipate to have sufficient cash to fund the business until late 2020.

Financial Highlights

Cash and cash equivalents were $105.6 million at June 30, 2018. We intend to continue to judiciously manage the use of cash and expect to have sufficient cash to fund the business until late 2020. Cellectis remains our majority shareholder with 70.24% of our common stock as of June 30, 2018.

Pursuant to the follow-on offering, in aggregate, the Company received net proceeds of approximately $57.0 million, after deducting underwriting discounts and commissions of $3.2 million and offering expenses totaling approximately $0.7 million. As part of the follow-on offering, Cellectis purchased 550,000 shares of common stock for a value of $8.3 million, the proceeds of which are included in the net proceeds of approximately $57.0 million.

For the three months ended June 30, 2018, we incurred losses from operations of $7.6 million and used net cash in operating activities of $2.3 million. For the six months ended June 30, 2018, we incurred losses from operations of $11.9 million and used net cash in operating activities of $8.8 million. The first semester cash spend includes spending on high-oleic soybean seed production to support our Spring 2018 planting of high-oleic soybeans.

Looking forward for the rest of 2018, we anticipate that our operating cash spend will be in the range of $2.0 to $2.2 million per month excluding working capital for grain purchases in the later part of 2018. Cash will be used to expand our R&D team to advance key products in the portfolio and continue to build our commercial capabilities.


       

 

Calyxt, Inc.

Condensed Balance Sheets

(Amounts in Thousands, Except Share Data and Per Share Data)

 
June 30,
2018
December 31,
2017
(unaudited)
Assets
Current assets:
Cash and cash equivalents $ 105,620 $ 56,664
Trade accounts receivable
Due from related parties 102 167
Prepaid expenses and other current assets 1,475 626
 
Total current assets 107,197 57,457
Property and equipment, net 21,337 14,353
Other long-term assets 307 357
 
Total assets $ 128,841   $ 72,167  
 
Liabilities and stockholders’ equity
Current liabilities:
Due to related parties $ 1,337 $ 1,350
Accounts payable 1,110 1,023
Accrued salaries, wages, and other compensation 627 945
Accrued liabilities 1,959 893
Current deferred revenue 9 43
 
Total current liabilities 5,042 4,254
Non-current deferred revenue 116 289
Finance lease obligations and other long term liabilities 17,444 10,148
 
Total liabilities 22,602 14,691
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized, 32,336,106· and 27,718,780 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 3 3
 
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, no shares
issued or outstanding as of June 30, 2018 and December 31, 2017, respectively
 
Additional paid-in capital 172,730 112,021
Accumulated deficit (66,494 ) (54,548 )
 
Total stockholders’ equity 106,239 57,476
 
Total liabilities and stockholders’ equity $ 128,841   $ 72,167  
 

       

Calyxt, Inc.

Condensed Statements of Operations

(Amounts in Thousands except Shares Outstanding and Per Share Amounts)

 
Three Months Ended
June 30,
Six Months Ended
June 30,
  2018         2017     2018         2017  
(unaudited)
Revenue $ 196 $ 223 $ 207 $ 278
Operating expenses:
Cost of revenue
Research and development 3,093 1,453 4,186 2,719
Selling, general, and administrative   4,595     2,010     7,809     3,588  
Total operating expenses   7,688     3,463     11,995     6,307  
Loss from operations (7,492 ) (3,240 ) (11,788 ) (6,029 )
Interest expense, net (72 ) (30 ) (140 ) (44 )
Foreign currency transaction loss   (12 )   (125 )   (18 )   (154 )
Loss before income taxes (7,576 ) (3,395 ) (11,946 ) (6,227 )
Income tax expense                
Net loss $ (7,576 ) $ (3,395 ) $ (11,946 ) $ (6,227 )
Basic and diluted loss per share $ (0.25 ) $ (0.17 ) $ (0.41 ) $ (0.32 )
Weighted average shares outstanding—basic and diluted   29,840,827     19,600,000     28,851,491     19,600,000  
 

                   

Calyxt, Inc.

Condensed Statement of Stockholders’ Equity

(Amounts in Thousands except Shares Outstanding)

 
Shares
Outstanding
Common
Stock
Additional
Paid-In
Capital
Accumulated
Deficit
Total
Stockholders’
Equity
Balances at December 31, 2017 27,718,780 $ 3 $ 112,021 $ (54,548 ) $ 57,476
 
Net loss (11,946 ) (11,946 )
Common shares issued upon exercise of options and other 559,826 1,241 1,241
Stock-based compensation 2,427 2,427
Issuance of common stock 4,057,500   -   57,041     57,041  
 
Balances at June 30, 2018 (unaudited) 32,336,106 $ 3 $ 172,730 $ (66,494 ) $ 106,239  
 

   

Calyxt, Inc.

Condensed Statements of Cash Flows

(Amounts in Thousands)

 
Six Months Ended
June 30,
2018     2017
(unaudited)
Operating activities
Net loss $ (11,946 ) $ (6,227 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation 371 268
Stock-based compensation 2,427 692
Unrealized transaction gain (loss) on related party activity 6 (156 )
Changes in operating assets and liabilities:
Trade accounts receivable - 110
Due to/from related parties 47 1,213
Prepaid expenses and other assets (799 ) (448 )
Accounts payable 87 284
Accrued salaries, wages, and other compensation (318 ) 10
Accrued liabilities 1,504 369
Deferred revenue   (207 )   (178 )
 
Net cash used in operating activities (8,828 ) (4,063 )
 
Investing activities
Purchases of property and equipment, net (498 ) (608 )
 
Net cash used in investing activities (498 ) (608 )
 
Financing activities
Advance from Parent - 3,000
Costs incurred related to the issuance of stock (665 ) (834 )
Proceeds from common stock issuance 57,706 -
Proceeds from the exercise of stock options   1,241     -  
 
Net cash provided by financing activities   58,282     2,166  
 
Net decrease in cash and cash equivalents 48,956 (2,505 )
Cash and cash equivalents—beginning of period   56,664     5,026  
 
Cash and cash equivalents—end of period $ 105,620   $ 2,521  
 
Supplemental cash flow information
Interest paid $ 207 $ -
Supplemental non-cash investing and financing transactions:
Property and equipment included in financing lease obligation $ 7,096 $ -
Offering costs in accounts payable and accrued liabilities $ 445 $ 1,269
 

About Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).

For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.

Calyxt Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.

CONTACT:
Media
Calyxt, Inc.
Jennifer Moore, 917-580-1088
VP Communications
media@calyxt.com
or
KCSA Strategic Communications
Caitlin Kasunich, 212-896-1241
ckasunich@kcsa.com
or
Nick Opich, 212-896-1206
nopich@kcsa.com
or
Investor Relations
Calyxt, Inc.
Simon Harnest, 646-385-9008
VP Corporate Strategy and Finance
simon.harnest@calyxt.com